<DOC>
	<DOCNO>NCT00615927</DOCNO>
	<brief_summary>Primary objective : - To evaluate activity imatinib mesylate hydroxyurea among patient progressive/recurrent grade II low-grade glioma ( LGG ) measure 12-month progression free survival Secondary objective : - To evaluate progression-free survival ( PFS ) , overall survival objective response rate among patient progressive/recurrent grade II LGG treat imatinib mesylate plus hydroxyurea - To assess safety tolerability imatinib mesylate + hydroxyurea population</brief_summary>
	<brief_title>Phase II Imatinib + Hydroxyurea Treatment Patients With Recurrent/Progressive Grade II Low-Grade Glioma ( LGG )</brief_title>
	<detailed_description>This open-label , single stage , uncontrolled , non-randomized Phase II study continuous , daily dos imatinib mesylate &amp; hydroxyurea adult patient progressive/recurrent Grade II low-grade glioma ( LGG ) . The treatment cycle define imatinib mesylate &amp; hydroxyurea administer daily 28 day purpose schedule evaluation . All patient receive 1 dos either imatinib mesylate hydroxyurea evaluable toxicity , whereas patient receive minimum 14 consecutive day study regimen evaluable response . Patients discontinue therapy prior receive 14 consecutive day study regimen regard ineligible evaluation response replace .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients grade II LGG recurrent/progressive follow prior surgical resection nondecreasing dose corticosteroid &gt; 25percent enlargement bidimensional measure/new lesion sequential image new &amp; /or worsening neurologic deficit Patients progressive/recurrent optic pathway tumor Patients measurable disease MRI/CT Interval &gt; 4 wks prior external beam radiation therapy ( XRT ) /chemo , &amp; enrollment protocol unless unequivocal evidence tumor progression &amp; patient recover expected toxicity associate prior therapy . Patients treat w chemo agent VP16 would normally retreat short interval may treat usual starting time even &lt; 4 wks last prior dose chemo Patients tumor biopsy &lt; 1 wk/surgical resection &lt; 2 wks prior start study drug Patients enrol arm B must &gt; 1 enzyme induce anticonvulsant &gt; 2 wks prior start study drug Patients nonincreasing dose steroid &gt; 7 day prior obtain baseline GdMRI brain Patients nonincreasing dose steroid &gt; 7 day prior start study drug Multifocal disease eligible Age &gt; 18 yr old Karnofsky Performance Status ( KPS ) &gt; 60 absolute neutrophil count ( ANC ) &gt; 1.5 x 10 9/L Hgb &gt; 9 g/dL Platelets &gt; 100 x 10 9/L K ≥ low limit normal ( LLN ) /correctable supplement Ca ≥ LLN/correctable supplement P ≥ LLN/correctable supplement aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) &amp; Alanine transaminase ( ALT ) / Serum Glutamic Pyruvate Transaminase ( SGPT } &lt; 2.5 x ULN Serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) Serum creatinine &lt; 1.5 x ULN/measured 24hr Creatinine Clearance &gt; 50 mL/min/1.73m2 Life expectancy ≥ 12wks Written inform consent obtain prior screen procedure Prior progressive disease/toxicity grade ≥ 3 prior hydroxyurea therapy Prior treatment imatinib/other platelet derive growth factor ( PDGF ) direct therapy Excessive risk bleeding define stroke &lt; 6 month , history central nervous system ( CNS ) /intraocular bleed , septic endocarditis Evidence intratumor hemorrhage pretreatment diagnostic imaging , except stable postoperative gr1 hemorrhage Pregnant/breast feeding , /adults reproductive potential employ effective method birth control Concurrent severe and/or uncontrolled medical disease could compromise participation study Acute/chronic liver disease Confirmed diagnosis HIV infection Impairment GI function/GI disease may significantly alter absorption imatinib Patients take Coumadin Patients receive investigational drug &lt; 2wks prior entry study/have recover toxic effect therapy Patients receive biologic , immunotherapeutic/cytostatic agent &lt; 1 wk prior entry study/have recover toxic effect therapy Patient &gt; 5 yr free another primary malignancy except : primary malignancy currently clinically significant/requiring active intervention , primary malignancy basal cell skin cancer/ cervical carcinoma situ . Existence malignant disease allow Patients surgery resection brain tumor &lt; 2 wks prior entry study/have recover side effect therapy Patients unwilling to/unable comply protocol Active systemic bleeding , GI bleeding/gross hematuria Gr2 / &gt; peripheral edema/central/systemic fluid collection Patients enroll arm A must receive EIAC &gt; 2 wks prior start study regimen Any follow exclusion criterion MRI imaging : Cardiac pacemaker Ferromagnetic metal implant approve safe use magnetic resonance ( MR ) scanner Claustrophobia Obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>glioblastoma multiforme ( GBM )</keyword>
	<keyword>GBM</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Droxia</keyword>
	<keyword>Hydrea</keyword>
	<keyword>Hydroxycarbamide</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Malignant brain tumor</keyword>
	<keyword>Recurrent glioblastoma multiforme</keyword>
	<keyword>Progressive glioblastoma multiforme</keyword>
</DOC>